Recognized in Best Lawyers since 2011 
Dr. Hans-Rainer Jaenichen is a German Patent Attorney, a registered European Patent Attorney, and a European Trademark and Design Attorney based in Munich, Germany. He has been a partner at the intellectual property law firm Vossius & Partner Patentanwälte Rechtsanwälte mbB since 1990. His practice focuses on Biotechnology Law and Life Sciences Practice, Intellectual Property Law, Patent Attorney services, and Pharmaceuticals Law. Dr. Jaenichen studied biology and earned a Ph.D. in molecular immunology.
Dr. Jaenichen works extensively with biotechnology and pharmaceutical inventions, advising clients on intellectual property strategies, patent prosecution, and related proceedings. He regularly lectures at international conferences and has authored numerous publications addressing intellectual property issues in biotechnology. He is a co-author of the book “From Clones to Claims,” which examines European Patent Office practice in biotechnology in comparison with approaches in the United States and Japan. The sixth edition of this publication was released in January 2016 together with Jürgen Meier, James F. Haley, Leslie McDonell, and Yoshinori Hosoda.
In his role as a Patent Attorney, Dr. Jaenichen represents clients before the European Patent Office (EPO), the German Patent and Trade Mark Office (GPTO), and German courts. His work includes patent prosecution, oppositions, revocation proceedings, infringement matters, and compulsory license proceedings, particularly in biotechnology and pharmaceutical technologies. He also advises companies on the development, organization, and management of patent portfolios related to life sciences innovations.
His technical experience spans biotechnology, molecular and microbiology, genetics, clinical sciences, and plant genetics. Matters he has handled involve cloned genes, recombinant protein production and glycosylation, antibodies such as monoclonal, single-chain, humanized, and recombinant antibodies, nucleic acid amplification technologies, RNAi, aptamers, ribozymes, antisense RNA, CRISPR systems, DNA polymerases, transgenic plants and animals, vaccines, recombinant viruses, gene therapy, enzyme replacement therapy, companion diagnostics, and biological implants.
Working closely with colleagues in the chemistry department at Vossius & Partner Patentanwälte Rechtsanwälte mbB, Dr. Jaenichen also addresses pharmaceutical and pharmacological inventions, including traditional chemical active ingredients and recombinant agents identified through methods such as combinatorial chemistry and high-throughput screening. The firm’s work in this area includes matters involving the registration and enforcement of Supplementary Protection Certificates (SPCs).
Dr. Jaenichen has participated in infringement litigation involving DNA molecules, enzymes, antibodies directed at multiple targets, recombinant proteins, bisphosphonates, and medical uses of related compounds. Through this work, he assists clients in navigating intellectual property issues that arise during the development and commercialization of biotechnology and pharmaceutical products.
He is a supporting member of the Max Planck Society (Max-Planck-Gesellschaft) and serves on the Board of Trustees of the Munich Intellectual Property Law Center (MIPLC). Dr. Jaenichen was also invited to participate in the 2012 Banbury Conference on patenting genes.
